気になる企業 – Acepodia – ID6990 [2020/01/12] ID6990

Acepodia

  • Cell Therapyをメインにするプライベートのバイオベンチャー
  • Headquarter : Alameda, CA, US.

HER2抗原陽性の固形がんの治療にNK細胞-Antibody (Antibody Cell-Conjugation:ACC technology)を使用した臨床試験の開始がFDAにより承認された(2020/01/09)

Acepodia – がん免疫療法、独自技術は、ACC (Antibody Cell Conjugation) technology platform, ACE1702 program for HER2+ cancers.

1. ACE1702 : HER2 (Endometrial cancer, ovarian cancer, breast cancer, gastric cancer)
2. ACE1708 : PD-L1 (Lung cancers, melanoma, head and neck cancer, and other carcinomas)
3. ACE1755 : CVD19 (B-cell lymphoma, chronic, CD20 (lymphocytic leukemia)

https://www.acepodia.com

Acepodia Announces FDA Clearance of IND for its NK Cell Therapy Drug Candidate ACE1702 to Treat Patients with HER2-expressing Solid Tumors

https://pipelinereview.com/index.php/2020010973481/Antibodies/Acepodia-Announces-FDA-Clearance-of-IND-for-its-NK-Cell-Therapy-Drug-Candidate-ACE1702-to-Treat-Patients-with-HER2-expressing-Solid-Tumors.html

関連記事